Clinical Trials Browser

Phase 1/2 × OTHER × milatuzumab × Clear all

NCT00989586 2017-02-06

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Completed

35 enrolled 11 charts

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00868478 2010-06-02

The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell